Bei Jing Ri Bao Ke Hu Duan·2025-09-11 03:59Group 1 - The core finding of the study indicates that the innovative drug Tislelizumab (百泽安) shows significant overall survival benefits for non-small cell lung cancer (NSCLC) patients, with a 4-year overall survival rate exceeding 72.3% for perioperative treatment and a 5-year overall survival rate of 20.1% for second/third-line treatment of advanced NSCLC [1][2] - The study highlights that the overall survival benefit is considered the "gold standard" for evaluating the efficacy of anti-tumor drugs, filling a data gap for Tislelizumab in perioperative treatment of NSCLC [2] - The research demonstrates that the neoadjuvant chemotherapy combined with Tislelizumab significantly reduces the risk of death by 35% for resectable NSCLC patients, with a notable 72.3% of patients surviving beyond 4 years [1][2] Group 2 - The "Healthy China Action - Cancer Prevention and Control Action Implementation Plan (2023-2030)" aims to achieve an overall cancer 5-year survival rate of 46.6% by 2030, emphasizing the critical need for improved lung cancer outcomes, as the current 5-year relative survival rate for all patients is only 28.7% [1] - The transition of PD-1 immune therapy, represented by Tislelizumab, from late-stage treatment to perioperative treatment for operable patients is expected to provide more cure possibilities for a broader lung cancer patient population, enhancing overall survival and quality of life [2]